Determinants and Mechanisms of the Low Fusogenicity and High Dependence on Endosomal Entry of Omicron Subvariants

Omicron has been shown to predominantly use the endosomal entry pathway, resulting in reduced lung tropism and reduced disease severity; however, the underlying mechanism is not fully understood. In addition, whether the most recent Omicron subvariants, including BA.5 and BA.2.75, use the same pathway as their ancestor for entry is currently not known. ABSTRACT The rapid spread and strong immune evasion of the SARS-CoV-2 Omicron subvariants has raised serious concerns for the global COVID-19 pandemic. These new variants exhibit generally reduced fusogenicity and increased endosomal entry pathway utilization compared to the ancestral D614G variant, the underlying mechanisms of which remain elusive. Here, we show that the C-terminal S1 mutations of the BA.1.1 subvariant, H655Y and T547K, critically govern the low fusogenicity of Omicron. Notably, H655Y also dictates the enhanced endosome entry pathway utilization. Mechanistically, T547K and H655Y likely stabilize the spike trimer conformation as suggested by increased molecular interactions in structural modeling and enhanced S1 shedding of their reversion mutants K547T and Y655H in viral producer cells. Importantly, the H655Y mutation also determines the low fusogenicity and enhanced dependence on the endosomal entry pathway of other Omicron subvariants, including BA.2, BA.2.12.1, BA.4/5, and BA.2.75. Together, these results uncover mechanisms governing Omicron subvariant entry and provide insights into altered Omicron tissue tropism and pathogenesis. IMPORTANCE Omicron has been shown to predominantly use the endosomal entry pathway, resulting in reduced lung tropism and reduced disease severity; however, the underlying mechanism is not fully understood. In addition, whether the most recent Omicron subvariants, including BA.5 and BA.2.75, use the same pathway as their ancestor for entry is currently not known. In this study, we show that T547K and H655Y mutations in the C terminus of the S1 subunit critically determine the enhanced dependence on the endosomal entry pathway as well as the reduced cell-cell fusion activity of Omicron BA.1, BA.1.1, and other subvariants. Further experiments and molecular modeling suggest that H655Y and K547T stabilize the spike trimer conformation, likely contributing to the decreased fusogenicity and endosomal entry. Our work uncovers novel mechanisms underlying the distinct entry pathway of Omicron subvariants and advances our understanding of their biological characteristics.

[1]  J. Chan,et al.  Spike mutations contributing to the altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2 , 2022, Emerging microbes & infections.

[2]  Qian Wang,et al.  Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5 , 2022, Nature.

[3]  D. Barouch,et al.  Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5 , 2022, The New England journal of medicine.

[4]  G. Lozanski,et al.  Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants , 2022, The New England journal of medicine.

[5]  Fei Shao,et al.  BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection , 2022, Nature.

[6]  Lihua Gao,et al.  Long-range enhancement of N501Y-endowed mouse infectivity of SARS-CoV-2 by the non-RBD mutations of Ins215KLRS and H655Y , 2022, Biology direct.

[7]  G. Lozanski,et al.  Differential Evasion of Delta and Omicron Immunity and Enhanced Fusogenicity of SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants , 2022, bioRxiv.

[8]  Vineet D. Menachery,et al.  Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant , 2022, Cell Reports.

[9]  T. Zhou,et al.  Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2 , 2022, Cell Host & Microbe.

[10]  J. Gohda,et al.  SARS-CoV-2 Omicron spike H655Y mutation is responsible for enhancement of the endosomal entry pathway and reduction of cell surface entry pathways , 2022, bioRxiv.

[11]  D. Barouch,et al.  Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants , 2022, The New England journal of medicine.

[12]  J. Dushoff,et al.  Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa , 2022, Science.

[13]  H. Ullum,et al.  Occurrence and significance of Omicron BA.1 infection followed by BA.2 reinfection , 2022, medRxiv.

[14]  H. Mo,et al.  Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants , 2022, bioRxiv.

[15]  Ruhong Yan,et al.  Omicron adopts a different strategy from Delta and other variants to adapt to host , 2022, Signal Transduction and Targeted Therapy.

[16]  K. Swanson,et al.  Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2 , 2022, Cell Host & Microbe.

[17]  Frances E. Muldoon,et al.  Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity , 2022, Nature.

[18]  S. Rowland-Jones,et al.  Omicron entry route , 2022, Nature Reviews Immunology.

[19]  Larissa B. Thackray,et al.  SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters , 2022, Nature.

[20]  S. Vermund,et al.  Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination , 2022, Nature Medicine.

[21]  Y. Kawaoka,et al.  Reduced pathogenicity of the SARS-CoV-2 omicron variant in hamsters , 2022, bioRxiv.

[22]  Nan Wang,et al.  Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron , 2022, Cell.

[23]  N. Krogan,et al.  Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and virus transmission , 2022, Cell Host & Microbe.

[24]  C. Riou,et al.  Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose , 2022, The Lancet.

[25]  Christina C. Chang,et al.  mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant , 2022, Cell.

[26]  M. Kraemer,et al.  Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa , 2021, Nature.

[27]  Jordan J. Clark,et al.  Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron , 2021, Nature.

[28]  P. Maes,et al.  Considerable escape of SARS-CoV-2 Omicron to antibody neutralization , 2021, Nature.

[29]  T. Zhou,et al.  Neutralization and Stability of SARS-CoV-2 Omicron Variant , 2021, bioRxiv.

[30]  Liyuan Liu,et al.  Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 , 2021, Nature.

[31]  Y. Kawaoka,et al.  Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation , 2021, Nature.

[32]  H. Mouquet,et al.  SARS‐CoV‐2 Alpha, Beta, and Delta variants display enhanced Spike‐mediated syncytia formation , 2021, The EMBO journal.

[33]  S. Bhatt,et al.  SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion , 2021, Nature.

[34]  M. Giacca,et al.  The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets , 2021, Nature Microbiology.

[35]  D. O’Connor,et al.  Transmission of SARS-CoV-2 in domestic cats imposes a narrow bottleneck , 2021, PLoS pathogens.

[36]  Vineet D. Menachery,et al.  Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis , 2021, Nature.

[37]  R. Rottier,et al.  SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site , 2021, eLife.

[38]  B. Haynes,et al.  D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease Cleavage at the S1/S2 Junction , 2020, Cell Reports.

[39]  G. Lozanski,et al.  Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers, and convalescent plasma donors , 2020, JCI insight.

[40]  D. A. Stein,et al.  TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells , 2020, Life Science Alliance.

[41]  Shinji Makino,et al.  An Infectious cDNA Clone of SARS-CoV-2 , 2020, Cell Host & Microbe.

[42]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[43]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[44]  J. Luban SARS-CoV-2 , 2020 .